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Background: The ideal prostate-specific antigen (PSA) doubling time (PSADT) threshold for identifying patients at
high-risk for poor clinical outcome following salvage radiation therapy (SRT) has not been well established. We
sought to assess what PSADT threshold is most clinically prognostic in this setting.
Methods: 575 patients who received SRT at a single institution for biochemical recurrence after radical
prostatectomy were retrospectively reviewed. We assessed the impact of pre-SRT PSADT on biochemical failure (BF),
distant metastasis (DM), prostate cancer-specific mortality (PCSM), and overall mortality (OM). Kaplan-Meier methods,
hazard ratio (HR) assessment, and Cox Proportional Hazard models were used to assess the discriminatory ability of
various PSADT thresholds.
Results: Sufficient data to calculate PSADTs were available for 277 patients. PSADT was prognostic for BF, DM, PCSM,
and OM on univariate analysis regardless of threshold. HR assessment identified 6 months as a strong threshold. No
statistically significant difference was observed in BF, DM, PCSM, or OM between patients with PSADT <3 (n=40) and
3–6 months (n=61) or between 6–10 (n=62) and >10 months (n=114). However significant differences were seen in BF
(HR:2.2, [95%CI: 1.4-3.5], p<0.01) and DM (HR:2.2, [95%CI: 1.2-4.3], p=0.02) between a PSADT of 3–6 and 6–10 months.
On multivariate analysis a PSADT <6 months predicted BF (HR:2.0, [95%CI: 1.4-2.9], p=0.0001), DM (HR:2.0, [95%CI: 1.2-3.4],
p=0.01), and PCSM (HR:2.6, [95%CI: 1.1-5.9], p=0.02).
Conclusions: A pre-SRT PSADT <6 months was a strong predictor of outcomes in our data set, including PCSM. The
most common nomogram for SRT uses a 10-month PSADT threshold for assigning points used to assess BF following
SRT. If validated, our findings suggest that a PSADT threshold of <6 months should be considered for stratification of
patients in future clinical trials in this setting.
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Each year >150,000 patients in the United States will
undergo radical prostatectomy (RP) for prostate cancer
[1]. Up to 30% of these patients will eventually experience
biochemical failure (BF) as manifested by a rising prostate-
specific antigen (PSA) [2]. A rising PSA after RP can be
indicative of local recurrence, distant disease, or both.
Many patients who experience BF post-RP will go on to
receive salvage external beam radiation therapy (SRT).
Unfortunately, a suboptimal number of patients under-
going SRT obtain long-term recurrence free responses
[3]. It is likely that many of the patients who experience
biochemical failure (BF) after SRT represent a subset of
patients who harbor micrometastatic disease at the time
of SRT. Improved prognostic factors are needed to better
delineate the patients who have locally confined disease
and are thus most likely to respond favorably to SRT.
A short PSA doubling time (PSADT) is known to predict
both the development of metastasis (DM), prostate cancer-
specific mortality (PCSM), and increased overall mortality
(OM) in patients experiencing BF after RP [4-10]. Simi-
larly, a short PSADT after RP predicts worse clinical out-
comes following SRT, including an increased likelihood of
BF and development of distant metastasis [3,11-18]. To
our knowledge, a direct association between a short pre-
SRT PSADT and increased PCSM following SRT has yet
to be reported; however, others have noted an association
between a short pre-SRT PSADT and an improved overall
benefit of SRT [19,20]. Furthermore, the most clinically
useful PSADT threshold for defining high-risk patients has
not been well established. Frequently proposed PSADT
cut-points include 3, 6, 10, and 12 months [3,12-14,19]. A
well-known predictive tool for response to SRT, the
Stephenson nomogram and decision tree, utilizes a
PSADT threshold of 10 months [3].
We sought to determine the most clinically prognostic




Through an institutional review board approved analysis,
575 patients who received SRT at a single institution,
with or without androgen deprivation therapy (ADT),
for BF following RP were identified and retrospectively
reviewed. All patients received SRT between 1986 and
2010. SRT was defined as radiation therapy (RT) given
for a persistently elevated PSA ≥0.2 ng/mL post-RP and
any RT given for BF post-RP. Of the 575 SRT patients,
277 had sufficient PSA data available following BF to
calculate PSADTs and comprise the cohort for this ana-
lysis. PSADTs were calculated as previously defined [4].
All available PSA values from BF post-RP and the start
of SRT were used to calculate PSADT. UltrasensitivePSA values were not used to calculate PSADT. If a patient
was started on neoadjuvant ADT prior to SRT, PSADT
was calculated using only PSA values available before the
start of ADT.
Treatment
SRT was delivered using either three-dimensional con-
formal radiation therapy or intensity-modulated radiation
therapy. Prescribed SRT doses ranged from 64.8-68.4 Gy,
typically to the prostate bed only, with whole-pelvic radi-
ation therapy (WPRT) used in only 10% of patients. The
use of ADT was per physician discretion and was utilized
in 15% of patients. Standard patient follow-up consisted of
appointments 3–4 times per year for the first 2 years, then
twice a year through year 5, and annually thereafter.
Endpoints
The outcomes of interest for this study include biochemical
failure (BF), development of distant metastasis (DM), pros-
tate cancer-specific mortality (PCSM), and overall mortality
(OM). BF was defined as a serum PSA 0.2 ng/mL greater
than the post-SRT PSA nadir, followed by a consecutively
higher PSA value [3]. DM was defined as the develop-
ment of clinical, radiologic, or pathologic evidence of
metastasis. PCSM was defined as any death in a patient
with metastasis or hormone refractory disease, or any
death attributed to prostate cancer. OM was defined as
death from any cause.
Statistical analysis
The Chi-square test was utilized to compare categorical
variables. One-way analysis of variance (ANOVA) was
used for comparison of continuous variables. Concordance
index (c-index) values were calculated to quantify the
discriminatory ability of PSADT as a continuous variable
for predicting time to the various survival outcomes [21].
Ties in the predictor were not common given the con-
tinuous nature of PSADT but were included in the
calculation as 0.5 in the numerator. Kaplan-Meier methods,
hazard ratio (HR) assessment, and Cox Proportional Hazard
models were used to evaluate various PSADT thresholds.
All statistical analysis was performed using MedCalc
(v12.3.0.0, MedCalc Software, Mariakerke, Belguim).
Results
Patient characteristics
Sufficient data to calculate PSADTs was available for 277
patients (48%). Of the patients with available PSADTs,
median age was 65 years and median age-adjusted Charlson
co-morbidity index (CCMI) was 3 [22]. The median time
of follow up post-SRT was 83 months and median RT
dose was 68.4 Gy (interquartile range [IQR] 64.8-68.4 Gy).
The median PSADT was 7.9 months (IQR 4.3-15.8). Over-
all, 40 patients had a PSADT <3 months, 61 had a PSADT
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10 months, 114 had a PSADT >10 months, 96 had a
PSADT >12 months and only 18 patients with a PSADT
between 10 and 12 months.
Patient characteristics were stratified by a PSADT cut-
off of 6 months as this was the closest proposed thresh-
old to our median PSADT (Table 1). 101 patients had a
PSADT <6 months, and 176 had a PSADT >6 months.
No difference existed between the two groups with respect
to age, CCMI, SRT dose, use of WPRT, use of ADT, ADT
duration, pathologic T-stage, seminal vesicle involvement
(SVI), extra-capsular extension (ECE), presence of surgical
margins (SM), or lymph node invasion (LNI). Patients
with PSADT <6 months did have a statistically significant
higher pre-SRT PSAs (p<0.001). The difference in median
pre-SRT PSA was only 0.2 ng/mL higher for patients with
PSADTs <6 months and the groups had overlapping
interquartile ranges. Patients with PSADT <6 monthsTable 1 Patient pathologic, pre-treatment, and treatment
characteristics
PSADT
PSADT > 6 PSADT < 6 p-value
(n=176) (n=101)
Age Median (IQR) 65.5 (59.4-70.2) 62.8 (58.6-68.6) p=0.14*
CCMI Median (IQR) 3.0 (3.0-4.0) 3.0 (3.0-4.0) p=0.2*
Range 1.0-8.0 1.0-7.0
Pre-SRT PSA Median (IQR) 0.6 (0.4-1.1) 0.8 (0.5-1.75) p<0.001*
Range 0.1-6.3 0.2-17.4
SRT dose Median (IQR) 68.4 (64.8-68.4) 68.4 (64.8-68.4) p=0.05*
WPRT 11.4% 6.9% p=0.3**
ADT during SRT 12.5% 18.8% p=0.2**
ADT duration 5.9 (4.4-8.5) 6.1 (4.7-15.1) p=0.6*
Gleason score




T1-T2a 13.0% 6.3% p=0.15**
T2b-T2c 32.2% 27.5%
T3-T4 54.8% 66.3%
SVI 9.8% 16.8% p=0.13**
ECE 45.4% 52.5% p=0.3**
SM 43.2% 44.0% p=0.9**
LNI 2.1% 1.2% p=0.9**
Abbreviations: PSADT Prostate-specific antigen doubling time, PSA Prostate-
specific antigen, IQR Interquartile range, CCMI Charlson comorbidity index, SRT
Salvage radiation therapy, WPRT Whole-pelvic radiation therapy, ADT
Androgen deprivation therapy, pTstage Pathologic T stage, SVI Seminal vesicle
invasion, ECE Extra-capsular extension, SM Surgical margin, LNI Lymph node
involvement, *Analysis of variance, ** Chi-square.were also more likely to have a Gleason score of 8 to 10
than patients with PSADTs >6 months (p=0.02).
PSADT threshold determination
Using c-indices, PSADT was evaluated as a continuous
variable to establish its discriminatory ability. PSADT did
have prognostic significance for each end-point including:
BF (0.623), DM (0.670), PCSM (0.721), and OM (0.636).
Having established the prognostic association, we sought
to optimize a PSADT threshold. Hazard ratios (HR) with
95% confidence intervals were calculated for a range
of PSADT thresholds (<3, 3–6, 6–10, 10–18, and >18
months) relative to patients with a PSADT <3 months
for BF, DM, PCMS, and OM (Figure 1). From these fig-
ures, it is apparent that BF and DM outcomes in the 3–6
month group were very similar to the 0–3 month group,
and outcomes in the 6–10 month group were very similar
to those of the 10–18 and >18 month groups. This moti-
vated use of a 6 month threshold as opposed to 3 or 10
months. Analysis of these figures also demonstrated that
6 months is the ideal threshold for determining patients
at highest risk for BF (HR:2.3, [95%CI: 1.6-3.3], p<0.01)
and DM (HR:2.8, [95%CI: 1.7-4.6], p<0.01), as 6 months
discriminates between those at high-risk for BF and DM
(PSADT <6 months) and low-risk for BF and DM (>6
months). For PCSM, there appears to be a more continu-
ous decline in risk with increasing PSADT, with a particu-
larly notable difference in the 0–3 and the 3–6 month
groups. Nevertheless, 6 months still appears to be a suit-
able threshold for this outcome as well, as the decline in
risk for those with a PSADT >6 months is significantly
less steep than the increase in risk for PCSM for those
with a PSADT <6 months. An ideal cut-point for deter-
mining patients at highest risk for OM was less obvious
using this method.
Univariate analysis
By log-rank analysis, a short PSADT significantly pre-
dicted BF, DM, PCSM, and OM regardless of cut-off
point (3, 6, or 10 months, all p <0.05). Other significant
predictors of outcome on univariate analysis included
pre-SRT PSA, Gleason score, and SVI (Table 2). Patients
with PSADTs <3, 3–6, 6–10, and >10, were compared
(Figure 2). By log-rank test, there was no statistical dif-
ference in BF, DM, PCSM, or OM between patients with
PSADT <3 (n=40) and 3–6 months (n=61), and simi-
larly, no difference existed between those with a PSADT
of 6–10 (n=62) and >10 months (n=114). A difference
did exist in BF (HR:2.2, [95%CI: 1.4-3.5], p<0.01) and
DM (HR:2.2, [95%CI: 1.2-4.3], p=0.02) for patients with
a PSADT between 3–6 as compared to 6–10 months.
Lastly, patients with a PSADT <6 months were com-
pared on univariate analysis to those with a PSADT >6
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Figure 1 Analysis of Hazard Ratios. Hazard ratio comparisons with 95% confidence intervals for various PSADT thresholds for A) Biochemical Failure,
B) Metastasis, C) Prostate cancer-specific mortality, D) Overall mortality.
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p<0.01), DM (HR:2.8, [95%CI: 1.7-4.6], p<0.01), PCSM
(HR:3.3, [95%CI: 1.6-6.9], p<0.01), and had increased OM
(HR:1.8, [95%CI: 1.1-3.0], p=0.01) compared to the patients
with a PSADT >6 months.
Multivariate analysis
Multivariate analysis was performed using PSADT <6
months, pre-SRT PSA, Gleason score, SVI, ECE, and
SM (Table 3). After adjusting for other clinical variables
and controlling for SRT dose, the use of WPRT, and
age-adjusted CCMI, a PSADT <6 months was prognos-
tic for BF (HR:2.0, [95%CI: 1.4-2.9], p=0.0001), DM
(HR:2.0, [95%CI: 1.2-3.4], p=0.01), and PCSM (HR:2.6,
[95%CI: 1.1-5.9], p=0.02).
Discussion
PSADT after BF following RP is prognostic for clinical
outcomes as well as response to SRT [3-18]. Boorjian et al.
found that a PSADT <6 months strongly correlated with
the development of metastatic disease following RP [6].
Similarly, Pound et al. demonstrated that following RP, a
PSADT <10 months was prognostic for the develop-
ment of metastasis [4]. Furthermore, a PSADT <3 months
has been shown to be prognostic for increased prostate
cancer-specific mortality and decreased overall survival
following RP [7,10]. Similar to the results found in RP
series, a short PSADT is prognostic for poor clinicaloutcomes following SRT, with multiple PSADT thresh-
olds reported to be clinically relevant. Stephenson et al.
identified that a post-RP PSADT <10 months resulted
in increased risk for BF following SRT [3,12]. A number
of studies have looked at PSADT prior to SRT and asso-
ciations with BF or metastases with thresholds selected
between 3 and 12 months, although, to date, no studies
have evaluated an association between PSADT and PCSM
following SRT [11-18]. Interestingly, in our analysis using
PSADT as a continuous variable, the strongest association
as evaluated by c-index was between PSADT and PCSM
(c-index 0.721) which was greater than that observed for
more commonly reported end-points such as BF (0.623)
and DM (0.670).
As a result, we confirm that a short PSADT post-RP is
associated with poor clinical outcomes following SRT,
including increased rates of BF and DM. Additionally,
we establish that a rapid PSADT post-RP also increases
the risk of PCSM. In our data set, analysis of hazard ratios
and Kaplan-Meier curves demonstrated that a PSADT
threshold of 6 months appears to be the ideal cut-point
for predicting long-term response to SRT. This threshold
strongly predicted BF, DM, and PCSM on multivariate
analysis.
Predictive tools are needed to identify patients for
whom SRT is appropriate. The Stephenson nomogram is
one such tool, but only predicts for BF following SRT
and has not been reported for DM, PCSM, or OM [3].
Table 2 Univariate analysis
BF DM PCSM OM
PSADT < 6 months HR: 2.3 HR: 2.8 HR: 3.3 HR: 1.80
[95%CI: 1.6-3.3] [95%CI: 1.7-4.6] [95%CI: 1.6-6.9] [95%CI: 1.1-3.0]
p<0.0001 p<0.0001 p=0.0007 p=0.01
Pre-SRT PSA HR: 1.2 HR: 1.2 HR: 1.2 HR: 1.2
[95%CI: 1.1-1.3] [95%CI: 1.1-1.3] [95%CI: 1.1-1.3] [95%CI: 1.01-1.2]
p<0.0001 p<0.0001 p<0.0001 p=0.0003
ADT during SRT HR: 0.8 HR: 0.9 HR: 0.9 HR: 1.1
[95%CI: 0.5-1.2] [95%CI: 0.46-1.77] [95%CI: 0.3-2.4] [95%CI: 0.6-2.3]
p=0.3 p=0.8 p=0.8 p=0.7
Gleason score* HR: 1.5 HR: 1.8 HR: 2.0 HR: 1.2
[95%CI: 1.2-1.7] [95%CI: 1.4-2.4] [95%CI: 1.4-2.9] [95%CI: 0.9-1.5]
p<0.0001 p<0.0001 p=0.0002 p=0.18
SVI HR: 2.2 HR: 2.3 HR: 3.2 HR: 2.2
[95%CI: 1.3-3.7] [95%CI: 1.1-4.9] [95%CI: 1.1-9.9] [95%CI: 1.0-4.7]
p=0.0001 p=0.0034 p=0.002 p=0.008
ECE HR: 1.8 HR: 1.5 HR: 1.7 HR: 1.6
[95%CI: 1.3-2.5] [95%CI: 0.9-2.4] [95%CI: 0.8-3.4] [95%CI: 0.97-2.6]
p=0.0004 p=0.12 p=0.16 p=0.07
SM HR: 0.6 HR: 0.7 HR: 1.2 HR: 0.9
[95%CI: 0.5-0.9] [95%CI: 0.5-1.2] [95%CI: 0.6-2.4] [95%CI: 0.5-1.4]
p=0.005 p=0.3 p=0.7 p=0.5
LNI HR: 1.2 HR: 2.0 HR: 3.6 HR: 1.9
[95%CI: 0.4-4.3] [95%CI: 0.3-14.1] [95%CI: 0.3-47.7] [95%CI: 0.3-12.9]
p=0.7 p=0.3 p=0.06 p=0.4
Abbreviations: BF; Biochemical failure, DM; Distant metastasis, PCSM; Prostate cancer-specific survival, OM; Overall mortality, PSADT; Prostate-specific antigen
doubling time, PSA; Prostate-specific antigen, SRT; Salvage radiation therapy, SVI; Seminal vesicle invasion, ECE; Extra-capsular extension, SM; Surgical margin,
LNI; Lymph node involvement, HR; Hazard ratio, CI; Confidence interval, *Cox-proportional hazards.
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BF, the overall discriminatory power of the model leaves
significant room for improvement (c-index = 0.69) [3].
In our cohort, PSADT alone had a c-index of 0.623 for
predicting BF, resulting in only a minor reduction in dis-
criminatory power compared to the Stephenson nomo-
gram for predicting BF. This is not entirely surprising,
given that PSADT is the single largest point contributor
in the Stephenson nomogram, accounting for greater
than 25% of the total points possible. Nevertheless, im-
proved predictive tools are needed that can accurately
and reliably predict which patients who experience BF
following RP are appropriate candidates for SRT. Our
data, which require validation, suggest that PSADT should
be included in such nomograms, and that a threshold of
6 months would be most prognostic.
The utility of PSADT when addressing BF and PSCM
after SRT is worth discussing so that SRT is not improperly
selected only for patients based upon a long PSADT [23].
In our cohort, where all patients received SRT, those with aPSADT <6 months are less likely to obtain a durable re-
sponse to SRT compared to those with a longer PSADT,
and are most likely to die from prostate cancer. How-
ever, this does not mean that patients with a short
PSADT should not receive SRT. Two large retrospective
studies assessing the survival benefit of SRT for patients
experiencing BF following RP [19,20], where some re-
ceived SRT and others did not, identified the greatest
benefit in survival from SRT in those with the shortest
PSADT. Trock et al. found that comparing those treated
with or without SRT, prostate cancer-specific survival
was improved with SRT, but only in patients with a PSADT
<6 months [20]. In contrast, Cotter et al. later demon-
strated that SRT was effective in decreasing all-cause
mortality both in patients with a PSADT <6 and >6
months [19]. However, when analyzing patients without
co-morbidities, the risk reduction offered by SRT was
approximately 1.5 fold greater for patients with a PSADT
<6 months [19]. The primary outcome of interest in the
study by Cotter et al. was all-cause mortality (ACM).
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Figure 2 Kaplan-Meier Analysis of PSA Doubling Time. Freedom from biochemical failure (A), freedom from metastasis (B), cause-specific survival
(C), and overall survival (D) for patients stratified by PSADT.
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PSADT <6 months, and 34% for those with a PSADT >6
months. In our cohort, median follow-up post SRT was
4 years shorter, which resulted in a lower actuarial ACM
in both PSADT groups (33% for <6 months, and 20% for
>6 months). However, the difference in actuarial ACM
between those receiving SRT with a PSADT <6 months
and >6 months was quite similar when comparing the
Cotter cohort to our own (15% vs. 13%, respectively). As
a result, the Trock and Cotter studies suggest that pa-
tients with a short PSADT are at greatest risk for PCSMTable 3 Multivariate analysis
Biochemical failure Metastasis
Variable HR 95%CI p-value HR 95%CI p-valu
PSADT <6 months 2.0 1.4-2.9 0.0001 2.0 1.2-3.4 0.01
Pre-SRT PSA 1.1 1.03-1.2 0.01 1.2 1.1-1.3 0.001
Gleason score 1.2 1.01-1.5 0.03 1.6 1.2-2.1 0.002
SVI 1.4 0.8-2.2 0.2 1.6 0.8-3.3 0.2
ECE 1.6 1.1-2.4 0.01 1.1 0.6-2.0 0.7
SM 0.5 0.4-0.7 0.0002 0.6 0.3-0.9 0.03
SRT dose 1.0 0.9-1.1 0.5 1.0 0.9-1.2 0.5
WPRT 0.7 0.4-1.5 0.4 1.6 0.6-3.9 0.3
Age-adjusted CCMI 1.0 0.9-1.2 0.7 1.1 0.9-1.3 0.6
Abbreviations: PSADT; prostate-specific antigen doubling time, PSA; prostate-specific
extra-capsular extension, SM; surgical margin, WPRT; whole pelvis radiation therapy,but also most likely to benefit from SRT in terms of im-
proved survival. Paradoxically, previous studies (11–14)
and our data show that these patients are also the most
likely to develop metastasis and experience a prostate
cancer-specific death following SRT. These collective data
are consistent with the hypothesis that following BF after
RP, patients fall into two large categories: those with local-
ized disease only and those with pre-existing metastasis.
Those with a short PSADT are likely enriched for aggres-
sive disease that could be either local or systemic. Patients
with an aggressive recurrence (as represented by a shortProstate cancer-specific mortality Overall mortality
e HR 95%CI p-value HR 95%CI p-value
2.6 1.1-5.9 0.02 1.4 0.8-2.4 0.3
1.2 1.1-1.3 0.003 1.2 1.1-1.3 0.001
1.6 1.0-2.7 0.04 0.9 0.7-1.3 0.6
2.0 0.7-5.6 0.2 1.7 0.8-3.7 0.2
0.7 0.3-1.9 0.6 1.5 0.8-2.9 0.2
1.0 0.4-2.1 0.9 0.7 0.4-1.2 0.2
0.8 0.7-1.0 0.07 0.9 0.8-1.0 0.2
1.5 0.4-5.7 0.5 1.3 0.5-3.3 0.6
1.3 0.9-1.8 0.1 1.3 1.1-1.7 0.01
antigen, SRT; salvage radiation therapy, SVI; seminal vesicle invasion, ECE;
CCMI; charlson co-morbidity index, HR; hazard ratio, CI; confidence interval.
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from SRT and would be most likely to see an improve-
ment in PCSM, whereas patients with micrometastatic
spread outside of the treatment field would be least likely
to benefit from SRT. In contrast, those with a long PSADT
are likely to have less overall risk from their disease due to
its more indolent nature and are less likely to see an im-
provement in PCSM with SRT (albeit more likely to have
biochemical control following SRT). One can, therefore,
conclude that PSADT alone is not sufficient to identify
patients most likely to benefit from SRT in regard to all
clinical end-points; although it does identify those at the
greatest risk for PCSM who may have the most to gain
if there is no evidence of metastatic disease. As a result,
without improved means to identify metastasis, a short
PSADT should not be used to select those not to receive
SRT as this may remove this potentially curative therapy
from those at greatest risk for PCSM who actually have
the most to gain from SRT.
Limitations of this analysis include its retrospective
design, which necessitates validation of these findings,
and the fact that PSADTs could only be calculated for
48% of the SRT cohort. Unknown confounders may have
been present and have the potential to bias our results if
differences exist between the patients for whom PSADTs
could be calculated for and those in whom we were
unable to calculate PSADTs. However, no statistically
significant difference existed between those with and
without a determinable PSADT for any of our four pri-
mary outcomes of BF (p=0.3), DM (p=0.2), PCSM (p=0.1),
and OM (p=0.1).
Conclusions
In summary, a short PSADT after BF post-RP predicts
worse outcomes after SRT. A PSADT <6 months was
the best predictor of outcomes in our data set, which
was particularly true for BF and DM. We also establish
that a post-RP PSADT <6 months is prognostic for PCSM
following SRT on both univariate and multivariate ana-
lysis. The most common prognostic nomogram for SRT
uses PSADT <10 months as the cut-off point for assigning
points used to predict BF following SRT. Using a PSADT
of <6 months may improve the nomograms functionality.
However, since these data and the Stephenson nomogram
only analyzed patients treated with SRT, they can provide
information regarding the likelihood of biochemical con-
trol following SRT but, without data comparing outcomes
without SRT, cannot reliably predict those most likely to
benefit from SRT in regard to other end-points. Indeed,
those at the greatest likelihood of BF following SRT are
also those most likely to progress to DM and PCSM. If
SRT can prevent these events, then these patients have
the potential for greatest gain from SRT. Overall, im-
proved prognostic and predictive models are needed toidentify which patients are most likely to benefit from
SRT, and our findings, once validated, suggest that PSADT
should be included in such nomograms with a threshold
of 6 months.
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